Orion’s collaboration partner Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of darolutamide in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The submission is based on positive results from the pivotal Phase III ARANOTE trial which showed t

Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs) September 24, 2024 – Araris Biotech AG (“Araris”), a Swiss oncology biotech company developing next-generation antibody-drug conjugates (ADCs), today announced it has entered into an Agreement with Innate Pharma (“Innate”). Under the agreement, Innate will assign its portfolio of patents related to its ADC transglutaminase

Sept. 20, 2024 -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced advancing its artificial intelligence-powered Brain Network Analytics (BNA™) technology after successful research collaborations with Takeda Pharmaceutical Company Limited (“Takeda”) and Novartis, two global leaders in pharm

MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA Represents the second EMA approval of an MVA-BN-based vaccine for a younger population COPENHAGEN, Denmark, September 19, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II variation for IMVANEX® (MVA-BN) smallpox and mpox vaccine, exte

Sept. 15, 2024 -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, today announced they are entering into a strategic platform license (SPL) agreement. Under the terms of the agreement, Kama

Sept. 10, 2024 -- Alopexx, Inc., a clinical-stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the prevention and treatment of bacterial, fungal, and parasitic infections, today announced a collaboration with Bharat Biotech for the co-development and commercialization of Alopexx’s proprietary broad-spectrum anti-microbial vaccine, AV0328, in India and other low income and lower middle-income countries. Bharat Biotech is a pioneering biotech

Sept. 10, 2024 -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today provided an update on the status of the completion of its previously announced acquisition of Alimera Sciences, Inc. (“Alimera”) (Nasdaq: ALIM). We note the Alimera press release issued today. The Company continues to work in good faith toward closing of the acquisition. Any delay is a result of discussions regarding closing conditions, which the Company expects to resolve promptly. ANI Pharmaceuticals, I

Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients Aug. 30, 2024 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing tuspetinib, a highly differentiated oral kinase inhibitor for the treatment of patients with acute myeloid leukemia (AML), today announced that it received a $10 million loan through a Facility Agreement wi

Aug. 28, 2024 -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its Master Collaboration Agreement with AstraZeneca to develop and commercialize companion diagnostics (CDx) for AstraZeneca’s future therapies being developed to address chronic diseases. Under the agreement, QIAGEN will develop and validate a genotyping assay using QIAGEN’s syndromic testing platform QIAstat-Dx. The test will enable specialty care providers to potentially perform genotyping w

NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine Biosciences The once-daily 20 mg dose efficacy, safety and tolerability Phase 2 results support advancement to Phase 3 in schizophrenia in early 2025 The once-daily 20 mg dose met the primary endpoint, demonstrating a statistically significant 7.5-point improvement (p=0.011, 0.61 effect size) in the PANSS total score compa